Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Companies including Eli Lilly, Pfizer, and Roche have launched clinical trials of such compounds
This multi-receptor activation enables: GLP-1R activation enhances glucose-dependent insulin secretion and reduces appetite through hypothalamic signaling GIPR activation (highest potency: EC50 0.0643 nM) promotes insulin secretion and modulates lipid metabolism GCGR activation (EC50 5.79 nM) increases energy expenditure and promotes hepatic fat oxidation Combined receptor engagement produces dose-dependent reductions in body weight and improvements in glycemic control Research demonstrates that GLP3s balanced activation across three receptors produces superior metabolic effects compared to single or dual agonists, with phase 2 trials showing up to 24.2% weight reduction in 48 weeks[2]
By leveraging texture and ingredient design, brands can create products that encourage mindful consumption and enhance satisfaction while meeting essential nutritional needs
January 22, 2026
